• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调控 Cdc42 及其信号通路在癌症中的作用:小分子和 microRNA 作为新的治疗候选物。

Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.

机构信息

Department of Pathophysiology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China.

Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, 461 Bayi Road, Nanchang 330006, China.

出版信息

Molecules. 2018 Mar 29;23(4):787. doi: 10.3390/molecules23040787.

DOI:10.3390/molecules23040787
PMID:29596304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6017947/
Abstract

Despite great improvements in the diagnosis and treatment of neoplasms, metastatic disease is still the leading cause of death in cancer patients, with mortality rates still rising. Given this background, new ways to treat cancer will be important for development of improved cancer control strategies. Cdc42 is a member of the Rho GTPase family and plays an important role in cell-to-cell adhesion, formation of cytoskeletal structures, and cell cycle regulation. It thus influences cellular proliferation, transformation, and homeostasis, as well as the cellular migration and invasion processes underlying tumor formation. Cdc42 acts as a collection point for signal transduction and regulates multiple signaling pathways. Moreover, recent studies show that in most human cancers Cdc42 is abnormally expressed and promoting neoplastic growth and metastasis. Regarding possible new treatments for cancer, miRNA and small molecules targeting Cdc42 and related pathways have been recently found to be effective on cancer. In this review, we analyze the newly recognized regulation mechanisms for Cdc42 and Cdc42-related signal pathways, and particularly new treatments using small molecules and miRNAs to inhibit the abnormal overexpression of Cdc42 that may slow down the metastasis process, improve cancer therapy and lead to novel strategies for development of antineoplastic drugs.

摘要

尽管在肿瘤的诊断和治疗方面取得了重大进展,但转移性疾病仍然是癌症患者死亡的主要原因,死亡率仍在上升。鉴于这种背景,寻找新的癌症治疗方法对于制定改进的癌症控制策略将非常重要。Cdc42 是 Rho GTPase 家族的成员,在细胞间黏附、细胞骨架结构的形成和细胞周期调控中发挥重要作用。因此,它影响细胞增殖、转化和动态平衡,以及肿瘤形成所涉及的细胞迁移和侵袭过程。Cdc42 作为信号转导的集合点,调节多种信号通路。此外,最近的研究表明,在大多数人类癌症中,Cdc42 异常表达,促进肿瘤生长和转移。关于癌症的可能新治疗方法,最近发现靶向 Cdc42 和相关途径的 miRNA 和小分子对癌症有效。在这篇综述中,我们分析了新发现的 Cdc42 及其相关信号通路的调节机制,特别是使用小分子和 miRNA 抑制 Cdc42 的异常过表达的新治疗方法,这可能会减缓转移过程,改善癌症治疗,并为开发抗肿瘤药物提供新策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/5650d4799811/molecules-23-00787-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/09fcec449087/molecules-23-00787-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/3357532eb9b4/molecules-23-00787-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/5650d4799811/molecules-23-00787-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/09fcec449087/molecules-23-00787-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/3357532eb9b4/molecules-23-00787-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f647/6017947/5650d4799811/molecules-23-00787-g003.jpg

相似文献

1
Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.调控 Cdc42 及其信号通路在癌症中的作用:小分子和 microRNA 作为新的治疗候选物。
Molecules. 2018 Mar 29;23(4):787. doi: 10.3390/molecules23040787.
2
Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.Cdc42信号通路抑制作为Ras相关癌症的治疗靶点
Curr Med Chem. 2017;24(32):3485-3507. doi: 10.2174/0929867324666170602082956.
3
Cdc42: Role in Cancer Management.Cdc42:在癌症治疗中的作用。
Chem Biol Drug Des. 2015 Oct;86(4):432-9. doi: 10.1111/cbdd.12556. Epub 2015 Apr 7.
4
miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer.miR-133是胃癌中CDC42-PAK信号通路的关键负调控因子。
Cell Signal. 2014 Dec;26(12):2667-73. doi: 10.1016/j.cellsig.2014.08.012. Epub 2014 Aug 22.
5
Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines.Cdc42 在肺癌中的表达分析及其在肺癌细胞系中受姜黄素调节。
Int J Oncol. 2012 May;40(5):1561-8. doi: 10.3892/ijo.2012.1336. Epub 2012 Jan 17.
6
miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42.miR-330 通过靶向 Cdc42 调节结直肠癌细胞的增殖。
Biochem Biophys Res Commun. 2013 Feb 15;431(3):560-5. doi: 10.1016/j.bbrc.2013.01.016. Epub 2013 Jan 18.
7
Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.Cdc42 负向调节高度侵袭性乳腺癌细胞的内在迁移。
J Cell Physiol. 2012 Apr;227(4):1399-407. doi: 10.1002/jcp.22853.
8
Targeting Rac and Cdc42 GTPases in Cancer.靶向癌症中的 Rac 和 Cdc42 GTPases。
Cancer Res. 2018 Jun 15;78(12):3101-3111. doi: 10.1158/0008-5472.CAN-18-0619. Epub 2018 Jun 1.
9
Molecular subversion of Cdc42 signalling in cancer.癌组织中 Cdc42 信号的分子颠覆。
Biochem Soc Trans. 2021 Jun 30;49(3):1425-1442. doi: 10.1042/BST20200557.
10
Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42.通过调节Cdc42的GTP水解速率来影响细胞转化。
Biochemistry. 2006 Jun 27;45(25):7750-62. doi: 10.1021/bi060365h.

引用本文的文献

1
Heritable Tissue-Specific Gene Expression Associates With Chronic Wound Microbial Species.可遗传的组织特异性基因表达与慢性伤口微生物种类相关。
Wound Repair Regen. 2025 Jul-Aug;33(4):e70055. doi: 10.1111/wrr.70055.
2
Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy.CDC42基因中的突变作为免疫检查点抑制剂治疗的反应生物标志物。
Cancer Med. 2025 Jan;14(1):e70556. doi: 10.1002/cam4.70556.
3
PLGA-PEG Nanoparticles Loaded with Cdc42 Inhibitor for Colorectal Cancer Targeted Therapy.负载Cdc42抑制剂的PLGA-PEG纳米颗粒用于结直肠癌的靶向治疗。

本文引用的文献

1
Functional characterization of a novel somatic oncogenic mutation of .鉴定一种新型的. 体致瘤基因突变的功能特征。
Signal Transduct Target Ther. 2017 Dec 22;2:17063. doi: 10.1038/sigtrans.2017.63. eCollection 2017.
2
microRNAs Make the Call in Cancer Personalized Medicine.微小RNA在癌症个性化医疗中发挥关键作用。
Front Cell Dev Biol. 2017 Sep 22;5:86. doi: 10.3389/fcell.2017.00086. eCollection 2017.
3
PIK3CB/p110β is a selective survival factor for glioblastoma.PIK3CB/p110β 是胶质母细胞瘤的选择性生存因子。
Pharmaceutics. 2024 Oct 6;16(10):1301. doi: 10.3390/pharmaceutics16101301.
4
Identification of PPREs and PPRE associated genes in the human genome: insights into related kinases and disease implications.鉴定人类基因组中的 PPREs 和 PPRE 相关基因:相关激酶的深入了解及疾病影响。
Front Immunol. 2024 Oct 2;15:1457648. doi: 10.3389/fimmu.2024.1457648. eCollection 2024.
5
Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy.发现具有良好药代动力学特征和体内抗癌疗效的 CDC42 抑制剂。
J Med Chem. 2024 Jun 27;67(12):10401-10424. doi: 10.1021/acs.jmedchem.4c00855. Epub 2024 Jun 12.
6
RhoJ: an emerging biomarker and target in cancer research and treatment.RhoJ:癌症研究与治疗中的新兴生物标志物和靶标。
Cancer Gene Ther. 2024 Oct;31(10):1454-1464. doi: 10.1038/s41417-024-00792-6. Epub 2024 Jun 10.
7
MRLC controls apoptotic cell death and functions to regulate epidermal development during planarian regeneration and homeostasis.MRLC 控制细胞凋亡,在涡虫再生和稳态过程中调节表皮发育。
Cell Prolif. 2024 Jan;57(1):e13524. doi: 10.1111/cpr.13524. Epub 2023 Jun 25.
8
Molecular dynamics simulations reveal the inhibition mechanism of Cdc42 by RhoGDI1.分子动力学模拟揭示 RhoGDI1 抑制 Cdc42 的机制。
J Comput Aided Mol Des. 2023 Jul;37(7):301-312. doi: 10.1007/s10822-023-00508-2. Epub 2023 Jun 7.
9
PI3K Functions Downstream of Cdc42 to Drive Cancer phenotypes in a Melanoma Cell Line.PI3K 在下游的 Cdc42 驱动黑色素瘤细胞系中的癌症表型。
Small GTPases. 2023 Dec;14(1):1-13. doi: 10.1080/21541248.2023.2202612.
10
Cycloartocarpin Inhibits Migration through the Suppression of Epithelial-to-Mesenchymal Transition and FAK/AKT Signaling in Non-Small-Cell Lung Cancer Cells.环阿尔廷烷二萜通过抑制非小细胞肺癌细胞上皮间质转化和 FAK/AKT 信号通路抑制迁移。
Molecules. 2022 Nov 22;27(23):8121. doi: 10.3390/molecules27238121.
Neuro Oncol. 2018 Mar 27;20(4):494-505. doi: 10.1093/neuonc/nox181.
4
Alterations in IQGAP1 expression and localization in colorectal carcinoma and liver metastases following oxaliplatin-based chemotherapy.基于奥沙利铂的化疗后结直肠癌及肝转移灶中IQGAP1表达和定位的改变。
Oncol Lett. 2017 Sep;14(3):2621-2628. doi: 10.3892/ol.2017.6525. Epub 2017 Jul 5.
5
From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.从 bench(实验室)到 bed(医院/家中):如何探索用于癌症治疗的有效的天然和合成 PAK1 阻滞剂/长寿促进剂。
Eur J Med Chem. 2017 Dec 15;142:229-243. doi: 10.1016/j.ejmech.2017.07.043. Epub 2017 Aug 9.
6
Overexpression of PAK1 Correlates with Aberrant Expression of EMT Markers and Poor Prognosis in Non-Small Cell Lung Cancer.PAK1的过表达与非小细胞肺癌中EMT标志物的异常表达及不良预后相关。
J Cancer. 2017 Jun 1;8(8):1484-1491. doi: 10.7150/jca.18553. eCollection 2017.
7
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.MLK3调节FRA-1和基质金属蛋白酶,以驱动三阴性乳腺癌细胞的侵袭和跨内皮迁移。
Oncogenesis. 2017 Jun 12;6(6):e345. doi: 10.1038/oncsis.2017.44.
8
Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.Cdc42信号通路抑制作为Ras相关癌症的治疗靶点
Curr Med Chem. 2017;24(32):3485-3507. doi: 10.2174/0929867324666170602082956.
9
MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer.微小RNA-29a通过直接靶向非小细胞肺癌中的CDC42发挥潜在的肿瘤抑制作用。
Oncol Lett. 2017 May;13(5):3896-3904. doi: 10.3892/ol.2017.5888. Epub 2017 Mar 22.
10
Negative regulation of CDC42 expression and cell cycle progression by miR-29a in breast cancer.miR-29a对乳腺癌中CDC42表达及细胞周期进程的负调控作用
Open Med (Wars). 2016 Mar 30;11(1):78-82. doi: 10.1515/med-2016-0015. eCollection 2016.